Sudan Loganathan

Stock Analyst at Stephens & Co.

(0.6)
# 2518
Out of 5,380 analysts
38
Total ratings
Success rate
Average return
17 Stocks
Name Action PT Current % Upside Ratings Updated
EXEL Exelixis
Upgrades: Overweight
29 60
45.72 31.23% 5 Jun 24, 2025
DCTH Delcath Systems
Reiterates: Overweight
25 25
13.87 80.25% 3 Jun 23, 2025
BPMC Blueprint Medicines
Downgrades: Equal-Weight
150 135
128.25 5.26% 3 Jun 3, 2025
ELEV Elevation Oncology
Downgrades: Equal-Weight
5 5
n/a n/a 4 Mar 24, 2025
IMNM Immunome
Reiterates: Overweight
30 30
8.95 235.2% 2 Mar 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
33 33
22.09 49.39% 2 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 8
2.86 179.72% 2 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
50 50
21.8 129.36% 2 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Equal-Weight
15 15
7.36 103.8% 2 Jan 22, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
31 31
11.97 158.98% 3 Jan 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
60 60
47.16 27.23% 2 Jan 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
1.69 195.86% 2 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
4
1.57 154.78% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
55
7.72 612.44% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
1.28 915.62% 1 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
100 100
8.3 1104.82% 2 May 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
20
2.06 870.87% 1 May 14, 2024